Human metapneumovirus infections in hematopoietic cell transplant recipients and hematologic malignancy patients

A systematic review

Dimpy P Shah, Pankil K. Shah, Jacques M. Azzi, Firas El Chaer, Roy F. Chemaly

Research output: Contribution to journalShort survey

16 Citations (Scopus)

Abstract

Over the past decade, reported incidence of human metapneumovirus (hMPV) has increased owing to the use of molecular assays for diagnosis of respiratory viral infections in cancer patients. The seasonality of these infections, differences in sampling strategies across institutions, and small sample size of published studies make it difficult to appreciate the true incidence and impact of hMPV infections. In this systematic review, we summarized the published data on hMPV infections in hematopoietic cell transplant recipients and patients with hematologic malignancy, focusing on incidence, hMPV-associated lower respiratory tract infection (LRTI), mortality, prevention, and management with ribavirin and/or intravenous immunoglobulins. Although the incidence of hMPV infections and hMPV-associated LRTI in this patient population is similar to respiratory syncytial virus or parainfluenza virus and despite lack of directed antiviral therapy, the mortality rate remains low unless patients develop LRTI. In the absence of vaccine to prevent hMPV, infection control measures are recommended to reduce its burden in cancer patients.

Original languageEnglish (US)
Pages (from-to)100-106
Number of pages7
JournalCancer Letters
Volume379
Issue number1
DOIs
StatePublished - Aug 28 2016
Externally publishedYes

Fingerprint

Metapneumovirus
Hematologic Neoplasms
Transplants
Respiratory Tract Infections
Infection
Incidence
Paramyxoviridae Infections
Respiratory Syncytial Viruses
Mortality
Ribavirin
Intravenous Immunoglobulins
Virus Diseases
Infection Control
Transplant Recipients
Sample Size
Antiviral Agents
Neoplasms
Vaccines
Viruses

Keywords

  • Cancer
  • HMPV
  • Leukemia
  • Lymphoma
  • Mortality
  • Stem cell transplantation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Human metapneumovirus infections in hematopoietic cell transplant recipients and hematologic malignancy patients : A systematic review. / Shah, Dimpy P; Shah, Pankil K.; Azzi, Jacques M.; El Chaer, Firas; Chemaly, Roy F.

In: Cancer Letters, Vol. 379, No. 1, 28.08.2016, p. 100-106.

Research output: Contribution to journalShort survey

Shah, Dimpy P ; Shah, Pankil K. ; Azzi, Jacques M. ; El Chaer, Firas ; Chemaly, Roy F. / Human metapneumovirus infections in hematopoietic cell transplant recipients and hematologic malignancy patients : A systematic review. In: Cancer Letters. 2016 ; Vol. 379, No. 1. pp. 100-106.
@article{f68abe2d1b8c4cdab9e6879bc53dbe5e,
title = "Human metapneumovirus infections in hematopoietic cell transplant recipients and hematologic malignancy patients: A systematic review",
abstract = "Over the past decade, reported incidence of human metapneumovirus (hMPV) has increased owing to the use of molecular assays for diagnosis of respiratory viral infections in cancer patients. The seasonality of these infections, differences in sampling strategies across institutions, and small sample size of published studies make it difficult to appreciate the true incidence and impact of hMPV infections. In this systematic review, we summarized the published data on hMPV infections in hematopoietic cell transplant recipients and patients with hematologic malignancy, focusing on incidence, hMPV-associated lower respiratory tract infection (LRTI), mortality, prevention, and management with ribavirin and/or intravenous immunoglobulins. Although the incidence of hMPV infections and hMPV-associated LRTI in this patient population is similar to respiratory syncytial virus or parainfluenza virus and despite lack of directed antiviral therapy, the mortality rate remains low unless patients develop LRTI. In the absence of vaccine to prevent hMPV, infection control measures are recommended to reduce its burden in cancer patients.",
keywords = "Cancer, HMPV, Leukemia, Lymphoma, Mortality, Stem cell transplantation",
author = "Shah, {Dimpy P} and Shah, {Pankil K.} and Azzi, {Jacques M.} and {El Chaer}, Firas and Chemaly, {Roy F.}",
year = "2016",
month = "8",
day = "28",
doi = "10.1016/j.canlet.2016.05.035",
language = "English (US)",
volume = "379",
pages = "100--106",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Human metapneumovirus infections in hematopoietic cell transplant recipients and hematologic malignancy patients

T2 - A systematic review

AU - Shah, Dimpy P

AU - Shah, Pankil K.

AU - Azzi, Jacques M.

AU - El Chaer, Firas

AU - Chemaly, Roy F.

PY - 2016/8/28

Y1 - 2016/8/28

N2 - Over the past decade, reported incidence of human metapneumovirus (hMPV) has increased owing to the use of molecular assays for diagnosis of respiratory viral infections in cancer patients. The seasonality of these infections, differences in sampling strategies across institutions, and small sample size of published studies make it difficult to appreciate the true incidence and impact of hMPV infections. In this systematic review, we summarized the published data on hMPV infections in hematopoietic cell transplant recipients and patients with hematologic malignancy, focusing on incidence, hMPV-associated lower respiratory tract infection (LRTI), mortality, prevention, and management with ribavirin and/or intravenous immunoglobulins. Although the incidence of hMPV infections and hMPV-associated LRTI in this patient population is similar to respiratory syncytial virus or parainfluenza virus and despite lack of directed antiviral therapy, the mortality rate remains low unless patients develop LRTI. In the absence of vaccine to prevent hMPV, infection control measures are recommended to reduce its burden in cancer patients.

AB - Over the past decade, reported incidence of human metapneumovirus (hMPV) has increased owing to the use of molecular assays for diagnosis of respiratory viral infections in cancer patients. The seasonality of these infections, differences in sampling strategies across institutions, and small sample size of published studies make it difficult to appreciate the true incidence and impact of hMPV infections. In this systematic review, we summarized the published data on hMPV infections in hematopoietic cell transplant recipients and patients with hematologic malignancy, focusing on incidence, hMPV-associated lower respiratory tract infection (LRTI), mortality, prevention, and management with ribavirin and/or intravenous immunoglobulins. Although the incidence of hMPV infections and hMPV-associated LRTI in this patient population is similar to respiratory syncytial virus or parainfluenza virus and despite lack of directed antiviral therapy, the mortality rate remains low unless patients develop LRTI. In the absence of vaccine to prevent hMPV, infection control measures are recommended to reduce its burden in cancer patients.

KW - Cancer

KW - HMPV

KW - Leukemia

KW - Lymphoma

KW - Mortality

KW - Stem cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=84975516000&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975516000&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2016.05.035

DO - 10.1016/j.canlet.2016.05.035

M3 - Short survey

VL - 379

SP - 100

EP - 106

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 1

ER -